1-[3-(2-氨基乙基)-1H-吲哚-5-基]乙酮 | 3551-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-[3-(2-氨基乙基)-1H-吲哚-5-基]乙酮
• 中文别名: 乙酰色胺；乙酰吲哚胺
• 英文名称: Acetryptine
• 英文别名: 1-<3-(2-aminoethyl)-1H-indol-5-yl>ethanone；1-(3-(2-aminoethyl)-1H-indol-5-yl)ethanone；1-[3-(2-amino-ethyl)-indol-5-yl]-ethanone；5-acetyl-1H-indole-3-ethanamine；5-Acetyl-tryptamin；1-[3-(2-aminoethyl)-1H-indol-5-yl]ethanone
• CAS: 3551-18-6
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: RAUGYAOLAMRLLZ-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C
• 沸点：
  411.3±30.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-[3-(2-氨基乙基)-1H-吲哚-5-基]乙酮 、 1,2-环己二酮 以 甲苯 为溶剂， 反应 2.0h， 以42%的产率得到2-<<2-(5-acetyl-1H-indol-3-yl)ethyl>imino>cyclohexanone
  参考文献：
  名称：

  Bobowski, George, Journal of Heterocyclic Chemistry, 1981, vol. 18, p. 1179 - 1187

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20130289033A1

  公开（公告）日：2013-10-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R 1 , R 2 , R 4 , R 5 , R 6 , E, n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , B, R 8 , and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明进一步涉及包括所述新型化合物的药物组合物以及制备所述新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m如权利要求中所定义。
• [EN] NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2012080220A1

  公开（公告）日：2012-06-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

  这项发明提供了新颖的化合物，以及这些新颖的化合物用作药物，更具体地用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病变的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成为特征的疾病。本发明还涉及利用这些新颖的化合物制备对治疗这种神经退行性疾病有用的药物。本发明还涉及包括这些新颖化合物的药物组合物，以及这些新颖化合物的制备方法。这些化合物的化学式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m的定义如索赔中所述。
• 3 amino alkyl indoles for use in treating migraine
  申请人：Glaxo Group Limited

  公开号：US04636521A1

  公开（公告）日：1987-01-13

  Compounds are disclosed of general formula (I) ##STR1## wherein R.sub.1 represents an alkyl, cycloalkyl, aryl or aralkyl group; R.sub.2, R.sub.3, R.sub.4, R.sub.6 and R.sub.7, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group; R.sub.5 represents a hydrogen atom or an alkyl, cycloalkyl, alkenyl or an aralkyl group; or R.sub.4 and R.sub.5 together form an aralkylidene group or R.sub.4 and R.sub.5 together with the nitrogen atom to which they are attached form a saturated monocyclic 5- to 7-membered ring; Alk represents an alkylene chain containing two or three carbon atoms which may be unsubstituted or substituted by not more than two C.sub.1-3 alkyl groups; and physiologically acceptable salts, solvates and bioprecursors thereof. The compounds are described as potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner using one or more pharmaceutically acceptable carriers or excipients. Various processes for the preparation of the compounds are disclosed including, for example, a process involving reaction of an aminoalkyl indole with a sulphonylating agent in order to introduce the --SO.sub.2 -- group at the 5-position on the indole nucleus.

  揭示了一般式(I)的化合物 ##STR1## 其中R.sub.1代表烷基、环烷基、芳基或芳基烷基；R.sub.2、R.sub.3、R.sub.4、R.sub.6和R.sub.7，可以相同也可以不同，每个代表氢原子或C.sub.1-3烷基；R.sub.5代表氢原子或烷基、环烷基、烯基或芳基烷基；或者R.sub.4和R.sub.5一起形成芳基烷基亚甲基团或者R.sub.4和R.sub.5与它们连接的氮原子一起形成饱和的单环5-至7-成员环；Alk代表含有两个或三个碳原子的烷基链，可以未经取代或通过不超过两个C.sub.1-3烷基取代；以及其生理上可接受的盐、溶剂和生物前体。这些化合物被描述为潜在用于治疗偏头痛，并且可以以常规方式制备为含有一种或多种药学上可接受的载体或赋形剂的药物组合物。揭示了各种制备这些化合物的方法，例如，涉及氨基烷基吲哚与磺酰化试剂反应以在吲哚核上的5位引入--SO.sub.2--基团的过程。
• 5-substituted 3-aminoalkyl indoles useful in treatment of migraine
  申请人：Glaxo Group Limited

  公开号：US04672067A1

  公开（公告）日：1987-06-09

  Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents CHO, COR.sub.8, CO.sub.2 R.sub.8, CONR.sub.9 R.sub.10, CSNR.sub.9 R.sub.10 or SO.sub.2 NR.sub.9 R.sub.10, where R.sub.8 represents alkyl, cycloalkyl, aryl or aralkyl, R.sub.9 represents hydrogen or alkyl, and R.sub.10 represents hydrogen or alkyl, cycloalkyl, aryl or aralkyl; R.sub.2, R.sub.3, R.sub.4, R.sub.6 and R.sub.7 each independently represents hydrogen or C.sub.1-3 alkyl; R.sub.5 represents hydrogen, or alkyl, cycloalkyl, alkenyl or aralkyl, or R.sub.4 and R.sub.5 together form an aralkylidene group or R.sub.4 and R.sub.5 together with the attached nitrogen atom form a saturated monocyclic 5- to 7-membered ring; and Alk represents C.sub.2-3 alkylene chain optionally substituted by not more than two C.sub.1-3 alkyl groups; and physiologically acceptable salts and solvates thereof. The compounds are potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner using pharmaceutically acceptable carriers or excipients. The compounds may be prepared by, for example, reaction of an aminoalkyl indole with an acid of formula R.sub.1 OH or an acylating agent corresponding thereto or with an inorganic cyanate or an organic isocyanate or isothiocyanate in order to introduce the desired R.sub.1 group at the 5-position on the indole nucleus.

  公式（I）的化合物被披露，其中R1代表CHO，COR8，CO2R8，CONR9R10，CSNR9R10或SO2NR9R10，其中R8代表烷基，环烷基，芳基或芳基烷基，R9代表氢或烷基，R10代表氢或烷基，环烷基，芳基或芳基烷基; R2，R3，R4，R6和R7各自独立地代表氢或C1-3烷基; R5代表氢，或烷基，环烷基，烯基或芳基烷基，或R4和R5一起形成芳基烷基亚甲基基团，或R4和R5与相连的氮原子一起形成饱和的单环5-至7-成员环; Alk代表C2-3烷基链，可选地被不超过两个C1-3烷基取代;以及其生理上可接受的盐和溶剂。这些化合物可能对偏头痛的治疗有用，并可以使用药学上可接受的载体或赋形剂按照传统方法制成制药组合物。这些化合物可以通过例如，将氨基烷基吲哚与公式R1 OH的酸或相应的酰化剂或与无机氰酸盐或有机异氰酸盐或硫氰酸盐反应来引入所需的R1基于吲哚核上的5位。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。